IMPLANON Drug Patent Profile

When do Implanon patents expire, and what generic alternatives are available?

Implanon is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-seven countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Implanon

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 28, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IMPLANON

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	26
Patent Applications:	2,304
DailyMed Link:	IMPLANON at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMPLANON

NDA:

021529

Dosage:

IMPLANT;IMPLANTATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMPLANON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Organon	EARLY_PHASE1
Mata Poli de Arajo	EARLY_PHASE1
Eastern Virginia Medical School	Phase 4

See all IMPLANON clinical trials

Pharmacology for IMPLANON

Drug Class

Progestin

US Patents and Regulatory Information for IMPLANON

IMPLANON is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006		DISCN	No	No			Y

Expired US Patents for IMPLANON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006

International Patents for IMPLANON

When does loss-of-exclusivity occur for IMPLANON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Egypt

Latvia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMPLANON around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	1729819
Germany	3879031
Slovenia	3417905

Supplementary Protection Certificates for IMPLANON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303306	C980027	Netherlands		PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
0303306	099C0041	Belgium		PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306	SPC/GB99/044	United Kingdom		PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: IMPLANON

Last updated: July 28, 2025

---

Introduction

IMPLANON, a long-acting reversible contraceptive (LARC), has established itself as a significant product within the global reproductive health market. Developed and marketed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., IMPLANON utilizes etonogestrel as its active ingredient, delivering effective contraception over a three-year period. Its unique mechanism, safety profile, and convenience have contributed to its growing market share. Analyzing IMPLANON’s market dynamics and financial trajectory involves examining its competitive landscape, regulatory environment, demand drivers, pricing strategies, and broader healthcare trends shaping its future.

---

Market Overview and Positioning

IMPLANON entered the contraceptive market as an innovative subdermal implant, addressing limitations associated with oral contraceptives such as adherence issues. Its introduction in multiple markets, including the U.S., Europe, and emerging economies, has coincided with increasing awareness and acceptance of LARC methods.

According to MarketResearch.com, the global contraceptives market was valued at approximately USD 20 billion in 2022, with LARC methods accounting for a significant growth segment due to rising focus on effective, long-term family planning solutions [1]. IMPLANON holds a competitive position against intrauterine devices (IUDs), contraceptive pills, and sterilization procedures, targeting women seeking discreet, long-term contraception.

The product's share is particularly prominent in developed markets, driven by higher healthcare access and insurance coverage, while emerging markets present expanding opportunities due to growing awareness and urbanization.

---

Key Drivers and Constraints

Demand Drivers

1. Evolving Family Planning Preferences
   Increasing preference for reversible, hassle-free contraception options boosts IMPLANON’s appeal. Surveys indicate a rising demand among women seeking discreet, low-maintenance methods [2].

2. Healthcare Policy and Reimbursement
   Policy shifts favoring preventative care and family planning services foster increased adoption, especially in countries with supportive healthcare policies.

3. Education and Awareness Campaigns
   Educational efforts by healthcare organizations improve acceptance, addressing misconceptions about long-term implants.

4. Technological Advancements
   Innovations in implant design, insertion procedures, and patient comfort enhance user experience and compliance.

Constraints

1. Regulatory Hurdles
   Variations in regulatory approval timelines across nations influence market penetration speed. FDA approval in the U.S. was granted in 2006, establishing early market presence [3].

2. Pricing and Reimbursement Policies
   Cost barriers, especially in low-income settings, hinder adoption. Insurance coverage discrepancies significantly impact sales volume.

3. Competitive Landscape
   Presence of alternative contraceptives, including other implants like Nexplanon, IUDs, and hormonal pills, creates substitutability risks.

4. Cultural and Societal Factors
   Societal attitudes towards contraception and medical procedures impact demand, particularly in conservative regions.

---

Financial Trajectory and Market Penetration

Revenue Trends

Since its launch, IMPLANON has demonstrated a steady revenue trajectory, marked by increased adoption in mature markets. In the U.S., for instance, the product contributed significantly to Merck’s reproductive health portfolio, with revenues augmented by practice expansion and reimbursement expansion.

Historically, the global revenues from contraceptive implants, including IMPLANON and Nexplanon (Nexplanon is a redesigned, radiopaque successor), have grown at approximately 7-9% annually, driven by expanding markets in Asia-Pacific and Latin America [4].

Pricing Strategies

Pricing varies significantly based on geography, healthcare system structure, and reimbursement policies. In developed markets, the implant’s cost ($400–$800 retail price) is often fully or partially reimbursed by insurance plans, facilitating higher uptake.

In emerging economies, manufacturers negotiate prices with governments or clinics, often reducing costs to improve affordability. The pricing elasticity directly influences sales volume and, consequently, revenue growth.

Market Penetration and Growth Opportunities

The global implant market is projected to reach USD 3 billion by 2030, with LARC segments experiencing double-digit growth rates, buoyed by increasing global contraceptive prevalence rates [5]. IMPLANON’s role as a key product within this segment ensures sustained revenue contributions, especially as newer formulations like Nexplanon improve performance metrics.

---

Regulatory and Competitive Developments

Recent regulatory actions bolster IMPLANON's market outlook. The U.S. FDA’s approval of Nexplanon in 2011, a more discreet, radiopaque variant of IMPLANON, expanded the product portfolio and market dynamics [6].

Competitors like Hormonal IUDs, Copper IUDs, and oral contraceptives influence strategic pricing and marketing. Merck’s focus on innovative delivery systems and patient-centric marketing sustains its competitive advantage.

Moreover, regulatory bodies’ emphasis on long-term safety and efficacy, coupled with post-marketing surveillance to monitor adverse events, determines product lifecycle and market confidence.

---

Impact of Broader Healthcare Trends

The increasing adoption of patient-centered care, telehealth, and digital health platforms extend the reach of contraceptive counseling. These trends support IMPLANON's integration into comprehensive family planning services.

Furthermore, rapid urbanization and rising female workforce participation support a demographic shift favoring reliable contraception options like IMPLANON.

---

Future Outlook and Financial Trajectory

The future financial trajectory of IMPLANON hinges on several factors:

• Market Expansion: Emerging markets, particularly in Asia-Pacific and Africa, are poised for accelerated growth as awareness and healthcare infrastructure improve.

• Product Innovation: Development of next-generation implants with longer durations or fewer procedural requirements can sustain interest and sales.

• Regulatory Approvals: Expansion into new markets depends heavily on regulatory acceptance, which may be expedited through strategic partnerships.

• Reimbursement and Pricing Strategies: Tailored approaches for different markets will maximize market penetration.

By conservative estimates, the global revenue contribution from IMPLANON and similar implants could grow at an annual rate of 6-8% over the next five years, tracking the broader LARC market’s expansion.

---

Key Takeaways

• IMPLANON holds a vital position in the global contraceptive market, with a proven track record in developed regions and significant growth potential in emerging markets.
• Market dynamics are driven by patient preferences for long-term, reversible contraception, supported by favorable healthcare policies, but challenged by regulatory and economic barriers.
• Financial performance remains robust, with revenue growth aligned with the expanding global LARC market, bolstered by product innovation and strategic positioning.
• Competitive pressure and societal factors necessitate ongoing innovation, targeted marketing, and strategic regional expansion.
• The trajectory for IMPLANON's revenues appears positive, contingent upon continued regulatory approval and uptake in underserved markets.

---

FAQs

1. How does IMPLANON compare with Nexplanon?
Nexplanon, a successor to IMPLANON, offers improved features such as radiopacity for easier localization via imaging, a more discreet removal process, and enhanced insertion techniques. While both contain etonogestrel, Nexplanon’s design improvements have expanded its market reach, with IMPLANON gradually phased out in favor of Nexplanon [6].

2. What factors influence IMPLANON’s pricing in different markets?
Pricing depends on local healthcare policies, reimbursement coverage, market competition, regulatory approval costs, and purchasing negotiations. Developed countries typically see higher prices supported by insurance, whereas lower-income markets benefit from subsidized pricing.

3. What regulatory challenges does IMPLANON face globally?
Variability in regulatory approvals across jurisdictions impacts market entry timelines. Factors such as safety data requirements, cultural acceptability, and local clinical trial mandates can delay or complicate approvals.

4. What is the outlook for IMPLANON's market share in the contraceptive segment?
With the increasing emphasis on long-acting reversible contraceptives, IMPLANON’s successor Nexplanon maintains a strong presence. As awareness campaigns expand and innovation continues, IMPLANON/Nexplanon’s combined market share is expected to grow, especially in regions expanding access to family planning.

5. How do healthcare trends impact IMPLANON’s adoption?
Digital health initiatives, telemedicine, and patient education improve awareness, addressing misconceptions and facilitating provider consultations. These trends support higher adoption rates and ongoing product demand.

---

References

[1] MarketResearch.com, “Global Contraceptives Market Size & Trends,” 2022.
[2] World Health Organization, “Family Planning Data,” 2021.
[3] U.S. Food and Drug Administration, “IMPLANON FDA Approval Announcement,” 2006.
[4] Grand View Research, “Long-Acting Reversible Contraceptives Market Size & Forecast,” 2022.
[5] Fortune Business Insights, “Contraceptive Devices Market Outlook,” 2023.
[6] Merck official publications, “Nexplanon & IMPLANON comparative overview,” 2012.

---

This analysis provides a comprehensive view of IMPLANON’s market landscape, investment potential, and strategic considerations, empowering healthcare stakeholders and investors to make informed decisions grounded in current trends and forecasts.